Training Doyens

Drugs produced in the pharmaceutical industry go through extensive quality controls to ensure a level of safety for the consumer or patient and yet when we talk about the process and quality controls in medical cannabis production, there is still a lot to learn. Our upcoming webinar discusses the recent federal government position on ending cannabis prohibition nationwide and what the regulations mean for GMP regulated industries. The webinar covers the following key areas: ·          HR policies and the new cannabis era (labor law challenges) ·          Common quality failures and threats ·          Challenges with the regulation of plant-based product LEARNING OBJECTIVES • Recent federal government position on ending Cannabis prohibition nationwide • FDA position on CBD and other cannabis derived products • Background from a regulatory standpo...

OVERVIEW When we discuss growing, producing, and manufacturing medical cannabis , we must think of it as a medicine. Medicine by definition, it is a substance intended to assist you with a medical condition, to help you feel better and not harm you. Drugs produced in the pharmaceutical industry go through extensive quality controls to ensure a level of safety for the consumer or patient. Yet when we talk process and quality controls in medical cannabis production, there is still a lot to learn. With all new events the FDA has stated that it “recognizes the significant public interest in cannabis and cannabis-derived compounds, particularly CBD.” However, there are many unanswered questions about the science, safety, and quality of products containing CBD. The agency is working on answering these questions through ongoing efforts including feedback from a recent FDA hearing and information and data gathering through a public docket. In order to start understanding what it...